NEWS SUMMARY: FERROVIAL, IBERDROLA, UNICAJA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Mixed performance ahead of results European stock markets saw significant dispersion, the CAC climbed +2.0%, the Ibex ended flat and the DAX fell. In the STOXX 600, which ended higher, the heavy gains of Consumer Goods stood ou...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: FERROVIAL, IBERDROLA, UNICAJA. EUROPA: PERNOD RICARD. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 3T’25 que se publicarán en España y Europa en los próximos días. Saldo mixto antes de los resultados Fuerte dispersión en las bolsas europeas, mientras el CAC rebotó un +2,0%, el Ibex terminó plano y el DAX...
Sanofi: Information concerning the total number of voting rights and shares - September 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry...
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Septembre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actio...
A director at Acciona SA sold 707 shares at 184.000EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
With the Telefonica CMD around the corner (4 November), we revisit our 1&1 valuation and reassess potential synergies from German mobile consolidation. We estimate a transaction could value 1&1 equity at €6.7bn (€38/ share, +90% upside) assuming synergies are split equally, or potentially higher if Vodafone were also to bid.
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM showed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Target...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...) AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) AlphaMedixTM a démontré des bénéfices prolongés et cliniquement significatifs ...
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors AlphaMedixTM showed prolonged and clinically meaningful benefits across PRRT-naïve and PRRT-exposed patients with unresectable or metastatic GEP-NETs, highlighting the potential of Targeted...
Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...) AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de tumeurs neuroendocrines gastro-entéro-pancréatiques (TNE-GEP) AlphaMedixTM a démontré des bénéfices prolongés et cliniquement significatifs...
NEWS SUMMARY: ECOENER, FERROVIAL, INDRA, MAPFRE, NATURGY, OHLA, SACYR, UNICAJA. Risk of snap election in France Most European stock markets fell, with the French CAC performing the worst due to the political instability of Macron’s Govt. In the STOXX 600, Energy (Brent rallied after OPEC+ “only” raised production by 137,000 b/d), Technology (boosted by the agreement between AMD and OpenAI) and Insurance led the gains, while Consumer Goods, Banks and Chemicals suffered the biggest drops. On the ...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ECOENER, FERROVIAL, INDRA, MAPFRE, NATURGY, SACYR, OHLA, UNICAJA. Riesgo de elecciones anticipadas en Francia Recortes en la mayoría de bolsas de Europa y con peor comportamiento del CAC francés por la inestabilidad política del ejecutivo de E. Macron. En el STOXX 600 dirigieron las subidas Energía (el Brent rebotó después de que la OPEP+ incrementase sólo 137.000 b/d), Tecnología (impulsado por el acuerdo entre AMD y OpenAI) y Seguros mientras qu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.